“If the patent system were constructed so that the judiciary could retroactively estimate that one-third of the patents protecting top-tier pharmaceuticals were invalid, inventors and companies would benefit from the rewards provided by the system. may have a hard time believing that it is not a scam.”
Case law defines failure to prosecute as an affirmative defense to a claim of infringement. Specifically, case law indicates that an asserted patent is unenforceable if the patentee causes unreasonable and unexplained delays in prosecution of the patent. Symbol Tech v Lemelson Medical, No. 04-1451 (Fed.Cir.2005). There is relatively little jurisprudence on the specifics of Laches. However, in 2021 the Federal Circuit states: presumption of prejudice”. Gil Hyatt vs Hirschfeld (Fed. Cir. 2021).what does this mean or what does this mean Hyatt case?
The pharmaceutical sector is insightful about the potential scope of this dictum, given the frequent reliance on pharmaceutical patents to at least partially justify billions of dollars of investment in research and development. This study therefore looks at the patents that protect the top 20 drugs in terms of revenue, listed in the Orange Book or Purple Book.
Data drill down
More specifically, the 20 drugs with the highest revenue in 2020 were examined. For each of these agents, IPDataLab is listed in either the Orange Book (which contains information on approved small molecule therapeutics) or the Purple Book (which contains information on approved biological therapeutics). Identified each patent. medicine. For each patent application, the earliest priority date and filing data of the application were also identified to determine the time difference between the priority date and filing date.
1, as shown in FIG. More than 1/3 of patents (87 out of 244) were identified as protecting the highest-revenue drugs, with a delay of more than six years from the earliest priority date to the filing date.
Notably, the size and temporal profile of the patent portfolio differed among these drugs. However, among the drugs with the highest revenue in 2020, 50% of these top drugs had at least one patent listed in the Orange Book or Purple. It is presumed invalid, according to the dictation of Hyatt’s lawsuit.(See Figure 2.)
Impact of anti-innovation
The Federal Circuit’s analysis of tort, Hyatt It leads to “presumption of prejudice”. This analysis focuses on whether there is prejudice against the public, but particularly where the means of invalidation are defined by judges rather than the legislative branch, patent owners and overall fairness and social It is also important to consider the potential impact on operational efficiency.
From the patent owner’s perspective, the United States Patent and Trademark Office (USPTO) fees (and likely attorney fees) are valid and enforceable if the patent application is granted and complies with statutory patentability requirements. It was paid with the expectation that it would lead to some patent. Patent. Instead, if the patent system were structured so that the judiciary could retrospectively presume that one-third of the patents protecting the best medicines were invalid, inventors and companies would You can have a hard time believing that the payoff isn’t a scam. Or that investing in product research and development is a sound business decision.
Additionally, consider the drug approval schedule. An entity may discover that a particular small molecule or macromolecule drug has shown potential to effectively treat a medical condition and may soon file a patent application. But then years of clinical trials were done to prove that the drug really effectively treats the condition, that the side effects are not so severe and/or uncommon as to outweigh the drug’s benefits, and that it is appropriate. identification of specific patient groups and specific dosages. After that, or in the meantime, the entity may submit and pursue an application with the Food and Drug Administration to request approval of the drug. Most of the time, promising drug candidates are dropped in response to suboptimal experimental or clinical data. If there is a delay of six years or more between the priority date and the filing date, the Federal Circuit’s proposed presumption of prejudice discourages companies from initially investing more money in each drug candidate for patent protection. You may be in a position where you have to choose between (even if most of your new drug candidates fail), or you may be in a position of weak patent protection for a very valuable drug. Missing estimates thus create a situation that facilitates even greater investment in research that is statistically very expensive and highly likely to fail.
So, in short, the Federal Circuit’s presumption to unfairly apply applications filed more than six years after the priority date will have significant ramifications for existing pharmaceutical patents. Judicially creating a new retroactive nullity presumption is a very risky move. Because the courts are not set up to ensure that diverse interests are adequately represented, or that potential chilling effects are adequately considered.
Image Source: Deposit Photo
Image ID: 204633772
Author: Alexis84
